Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam

Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center F4-217, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Pathogens and Global Health (Impact Factor: 1.66). 10/2003; 97(6):575-80. DOI: 10.1179/000349803225001427
Source: PubMed


Malarone, a fixed combination of atovaquone with proguanil (AP), has recently been recognized as a promising treatment against multidrug-resistant Plasmodium falciparum. In Vietnam, the first-line treatment for P. falciparum malaria is currently a combination of mefloquine and an artemisinin derivative, and the use of AP has not been explored. The aim of the present study, based in Vietnam, was to assess the efficacy of AP when used to treat P. falciparum recrudescences that had occurred after primary treatment with mefloquine-artesunate. All but two of the 39 patients investigated completed follow-up. The mean parasite- and fever-clearance times [and 95% confidence intervals (CI)] after AP treatment were 36 (30-42) and 21 (18-24) h, respectively. Most (32) of the 37 infections that were followed adequately appeared to be eradicated by the AP, the other five recrudescing once more. The overall cure 'rate' and (CI) was 86% (76%-98%). All of the patients tolerated the AP well. Atovaquone-proguanil appears to be a safe and promising alternative treatment for P. falciparum infections in South-east Asia, although the combination is relatively expensive and may not clear some infections with multidrug-resistant parasites.

1 Follower
11 Reads
  • Source
    • "In a study from Vietnam, it has been reported that the combination of atovaquone with proguanil (AP) yielded an overall cure rate of 86% to treat recrudescent P. falciparum infections that had occurred after primary treatment with other antimalarials. In their study, the authors recommended AP as a safe and promising alternative treatment for P. falciparum infections in South-East Asia [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Atovaquone is part of the antimalarial drug combination atovaquone-proguanil (Malarone) and inhibits the cytochrome bc1 complex of the electron transport chain in Plasmodium spp. Molecular modelling showed that amino acid mutations are clustered around a putative atovaquone-binding site resulting in a reduced binding affinity of atovaquone for plasmodial cytochrome b, thus resulting in drug resistance. The prevalence of cytochrome b point mutations possibly conferring atovaquone resistance in Plasmodium falciparum isolates in atovaquone treatment-naïve patient cohorts from Lambaréné, Gabon and from South Western Ethiopia was assessed. Four/40 (10%) mutant types (four different single polymorphisms, one leading to an amino acid change from M to I in a single case) in Gabonese isolates, but all 141/141 isolates were wild type in Ethiopia were found. In the absence of drug pressure, spontaneous and possibly resistance-conferring mutations are rare.
    Malaria Journal 02/2006; 5(1):112. DOI:10.1186/1475-2875-5-112 · 3.11 Impact Factor

  • [Show abstract] [Hide abstract]
    ABSTRACT: Malaria is an important aspect of public health in endemic countries, not in the least because malaria control is frustrated by the spreading risk of (multi-)drug resistant malaria. Many strategies and campaigns for malaria control were launched during the last century. However, notwithstanding certain successes, the safety of much of the population the malaria endemic regions is threatened by drug resistant malaria parasites. The current "Global Malaria Control Strategy" aims at application of artemisinin based combination therapy (ACT). Some nations have been particularly successful in applying ACT, such as China, Vietnam, Thailand, and Brazil. Artemisinin derivatives are very effective agents and safe for human use. Fetal neurotoxicity, as was found in animal experiments, has not been observed in humans, but it is acknowledged that data aggregation and post marketing surveillance are not yet optimal to exclude potential risks by the use of ACT. This paper describes a series studies of the use of artemisinins as monotherapy or in combination with mefloquine or piperaquine, also in comparison to a combination of atovaquone/proguanil for the treatment of P. falciparum and P. vivax malaria in the South of Vietnam.
    The International journal of risk & safety in medicine 04/2004; 16:217-222.
Show more

Similar Publications